Research progress in gut microbiota and metabolism in the pathogenesis of chronic urticaria.
10.11817/j.issn.1672-7347.2025.250217
- Author:
Meiyun JIANG
1
,
2
,
3
;
Jiayi WANG
1
;
Cong PENG
1
;
Jie LI
1
,
4
Author Information
1. Dermatology Hospital (Department of Dermatology), Xiangya Hospital, Central South University, Changsha
2. jmy2543@
3. com.
4. xylijie@csu.edu.cn.
- Publication Type:English Abstract
- Keywords:
chronic urticaria;
gut microbiota;
metabolite biomarkers;
metabolomics;
microbiota therapy;
pathogenesis
- MeSH:
Humans;
Gastrointestinal Microbiome/physiology*;
Chronic Urticaria/etiology*;
Dysbiosis/complications*;
Mast Cells
- From:
Journal of Central South University(Medical Sciences)
2025;50(7):1271-1281
- CountryChina
- Language:Chinese
-
Abstract:
Chronic urticaria (CU) is a persistent immune-mediated skin disease with an incompletely understood pathogenesis. As the largest micro-ecosystem in the human body, the gut microbiota participates in complex metabolic processes and produces a wide range of metabolites. The gut microbiota-metabolism axis plays a crucial role in the onset and progression of CU. Patients with CU commonly exhibit gut dysbiosis, characterized by a reduction in beneficial bacteria and an increase in opportunistic pathogens, accompanied by alterations in key metabolites. These changes may disrupt the intestinal barrier and modulate the function of immune cells such as mast cells and T cells, thereby triggering or aggravating distal cutaneous inflammation and contributing to CU pathophysiology. Certain bacterial taxa and metabolites hold promise as potential biomarkers for CU diagnosis, therapeutic response, and prognosis, while interventions targeting gut microbiota have demonstrated potential in ameliorating CU symptoms. Elucidating the characteristics and mechanistic roles of gut microbiota and metabolism in CU could provide a theoretical basis for developing novel individualized diagnostic and therapeutic strategies.
